Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Declines By 85.2%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 33,404 shares, a decrease of 85.2% from the May 31st total of 225,674 shares. Approximately 6.0% of the company’s stock are short sold. Based on an average daily trading volume, of 313,931 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC bought a new position in Shuttle Pharmaceuticals in the 4th quarter worth about $26,000. Boothbay Fund Management LLC purchased a new position in Shuttle Pharmaceuticals in the fourth quarter worth about $37,000. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals in the fourth quarter worth about $124,000. Finally, Connective Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals in the third quarter worth approximately $357,000. Hedge funds and other institutional investors own 4.58% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Stock Up 2.4%

Shares of SHPH opened at $3.78 on Friday. The stock has a market cap of $2.42 million, a P/E ratio of -0.08 and a beta of 0.18. The business’s 50 day moving average price is $6.44 and its 200-day moving average price is $11.15. Shuttle Pharmaceuticals has a 52 week low of $3.16 and a 52 week high of $55.90.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 earnings per share for the quarter.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .